Bank of America Corp Reports 4.1% Stake in Novavax Inc. (NVAX) via Schedule 13G/A

Bank of America Corporation filed a Schedule 13G/A on April 27, 2026, reporting a 4.1% ownership stake in Novavax Inc. (NVAX). The filing indicates that Bank of America beneficially owns 6,655,398 shares of common stock as of the event date on March 31, 2026. This represents an increase from a previously reported 0% position, though the filing is an amendment (Amendment No. 1). The shares are held by various subsidiaries, including BofA Securities, Inc., Bank of America N.A., Merrill Lynch Pierce Fenner & Smith, Inc., and Merrill Lynch International. According to the filing, Bank of America has shared voting power over 6,653,929 shares and shared dispositive power over the full 6,655,398 shares. The calculation of the 4.1% ownership is based on approximately 162.9 million outstanding shares of Novavax common stock. The securities were acquired in the ordinary course of business and are not held for the purpose of influencing or changing the control of the issuer.